Mydicar is under clinical development by Sardocor and currently in Phase II for Congestive Heart Failure (Heart Failure). According to GlobalData, Phase II drugs for Congestive Heart Failure (Heart Failure) have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Mydicar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mydicar overview
Mydicar is under development for the treatment of pulmonary hypertension, DMD-related cardiomyopathy, diastolic heart failure, congestive heart failure and systolic heart failure. The drug candidate is administered as intracoronary infusion and through intratracheal route. It is a genetically-targeted enzyme replacement therapy and delivers the SERCA2a 3E13 viral genomes by using recombinant adeno-associated virus (AAV) as the vector.
It was also under development for the treatment of arteriovenous fistula, pulmonary arterial hypertension, advanced heart failure with left ventricular assist device (LVAD) including chronic heart failure.
Sardocor overview
Sardocor specializes for the treatment of patients with heart failure . The company is located in Irvine, California, United States.
For a complete picture of Mydicar’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
